Novartis India (BOM:500672) Tariff Resilience Score: 0/10 (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500672 Novartis India Ltd BOM:500672
59 GF Score
Price ₹1,626.25
GF Value ₹1,011.11
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis India Tariff Resilience Score?

Novartis India has the Tariff Resilience Score of 0, which implies that the company might have .

Novartis India has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Novartis India might have .

Novartis India  (BOM:500672) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Novartis India Tariff Resilience Score Related Terms

BOM:500672
59GF Score
Novartis India Ltd BOM:500672
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novartis India (BOM:500672) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis India stock appears to be overvalued. The current stock price of ₹1,626.25 is trading 60.8% above its estimated GF Value™ of ₹1,011.11. GuruFocus considers Novartis India to be Significantly Overvalued.

Key valuation signals for BOM:500672:

  • Tariff Resilience Score: 0
  • GF Value™: ₹1,011.11 vs. price of ₹1,626.25 (60.8% above fair value)
  • GF Score™: 59/100 with 7 warning signs

No single metric tells the full story. See the BOM:500672 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis India Business Description

Other Exchanges NOVARTIND:India
Address Inspire BKC, Part of 601 & 701, Bandra Kurla Complex, Bandra (East), Mumbai, MH, IND, 400 051
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
59GF Score

Get the complete analysis for BOM:500672

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,626.25
Price
₹1,011.11
GF Value